Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues

Lisa M Rimsza, George Wright, Mark Schwartz, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Andreas Rosenwald, German Ott, James R. Cook, Raymond R. Tubbs, Rita M. Braziel, Jan Delabie, Thomas P Miller, Louis M. Staudt

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.

Original languageEnglish (US)
Pages (from-to)3727-3732
Number of pages6
JournalClinical Cancer Research
Volume17
Issue number11
DOIs
StatePublished - Jun 1 2011

Fingerprint

Nuclease Protection Assays
Germinal Center
Lymphoma, Large B-Cell, Diffuse
Paraffin
Formaldehyde
B-Lymphocytes
Gene Expression Profiling
Transcriptome
Clinical Trials
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. / Rimsza, Lisa M; Wright, George; Schwartz, Mark; Chan, Wing C.; Jaffe, Elaine S.; Gascoyne, Randy D.; Campo, Elias; Rosenwald, Andreas; Ott, German; Cook, James R.; Tubbs, Raymond R.; Braziel, Rita M.; Delabie, Jan; Miller, Thomas P; Staudt, Louis M.

In: Clinical Cancer Research, Vol. 17, No. 11, 01.06.2011, p. 3727-3732.

Research output: Contribution to journalArticle

Rimsza, LM, Wright, G, Schwartz, M, Chan, WC, Jaffe, ES, Gascoyne, RD, Campo, E, Rosenwald, A, Ott, G, Cook, JR, Tubbs, RR, Braziel, RM, Delabie, J, Miller, TP & Staudt, LM 2011, 'Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues', Clinical Cancer Research, vol. 17, no. 11, pp. 3727-3732. https://doi.org/10.1158/1078-0432.CCR-10-2573
Rimsza, Lisa M ; Wright, George ; Schwartz, Mark ; Chan, Wing C. ; Jaffe, Elaine S. ; Gascoyne, Randy D. ; Campo, Elias ; Rosenwald, Andreas ; Ott, German ; Cook, James R. ; Tubbs, Raymond R. ; Braziel, Rita M. ; Delabie, Jan ; Miller, Thomas P ; Staudt, Louis M. / Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 11. pp. 3727-3732.
@article{9b4659080b8e462a8ac62489b0d817e8,
title = "Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues",
abstract = "Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92{\%}. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.",
author = "Rimsza, {Lisa M} and George Wright and Mark Schwartz and Chan, {Wing C.} and Jaffe, {Elaine S.} and Gascoyne, {Randy D.} and Elias Campo and Andreas Rosenwald and German Ott and Cook, {James R.} and Tubbs, {Raymond R.} and Braziel, {Rita M.} and Jan Delabie and Miller, {Thomas P} and Staudt, {Louis M.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2573",
language = "English (US)",
volume = "17",
pages = "3727--3732",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues

AU - Rimsza, Lisa M

AU - Wright, George

AU - Schwartz, Mark

AU - Chan, Wing C.

AU - Jaffe, Elaine S.

AU - Gascoyne, Randy D.

AU - Campo, Elias

AU - Rosenwald, Andreas

AU - Ott, German

AU - Cook, James R.

AU - Tubbs, Raymond R.

AU - Braziel, Rita M.

AU - Delabie, Jan

AU - Miller, Thomas P

AU - Staudt, Louis M.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.

AB - Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.

UR - http://www.scopus.com/inward/record.url?scp=79957887434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957887434&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2573

DO - 10.1158/1078-0432.CCR-10-2573

M3 - Article

C2 - 21364035

AN - SCOPUS:79957887434

VL - 17

SP - 3727

EP - 3732

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -